deltatrials
Terminated PHASE1 INTERVENTIONAL 1-arm NCT04548700

Liposomal Mitoxantrone Hydrochloride Injection,Cyclophosphamide, Vincristine and Prednisone in the Treatment of PTCL

Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of Liposomal Mitoxantrone Hydrochloride Injection Combined With Cyclophosphamide, Vincristine and Prednisone in the Treatment of Untreated PTCL

Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Conditions Peripheral T Cell Lymphoma Treatment-naïve
Interventions Dose-expansion stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone Dose-finding stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone
Updated 7 times since 2020 Last updated: Mar 5, 2024 Started: Dec 24, 2020 Primary completion: Jun 30, 2023 Completion: Nov 30, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The sponsor has adjusted its R\&D strategy.

Other terminated trials from CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

More terminations from CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Other Peripheral T Cell Lymphoma trials with similar outcome

Browse all Peripheral T Cell Lymphoma trials

A PHASE1 clinical study on Peripheral T Cell Lymphoma and Treatment-naïve, this trial is terminated or withdrawn. The trial is conducted by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. and has accumulated 7 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshotNot Yet Recruiting~Sep 2021 – ~Nov 2023 · 26 months · monthly snapshotRecruiting~Nov 2023 – ~Apr 2024 · 5 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshotTerminated

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  3. Apr 2024 — Jul 2024 [monthly]

    Terminated PHASE1

    Status: Unknown Status → Terminated

  4. Nov 2023 — Apr 2024 [monthly]

    Unknown Status PHASE1

    Status: Recruiting → Unknown Status

  5. Sep 2021 — Nov 2023 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

▶ Show 2 earlier versions

  1. Jan 2021 — Sep 2021 [monthly]

    Not Yet Recruiting PHASE1

  2. Oct 2020 — Jan 2021 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Data source: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations